You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Clinical real-time resting state fMRI

    SBC: NeurInsight, LLC            Topic: 108

    DESCRIPTION provided by applicant Surgical resection of brain neoplasms aims at maximizing long term survival by gross total resection of tumor tissue while preserving the patientandapos s functional status Task based functional MRI fMRI is increasingly used as an adjunct to intra operative electrocorticography for mapping eloquent cortex but suffers a significant failure rate due to funct ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. An eHealth solution for posttraumatic stress and pain screening integrated in pediatric injury care

    SBC: Radiant Creative Group, LLC            Topic: NICHD

    DESCRIPTION provided by applicant Each year million US children are injured affecting the child his her family and society which often bears the cost Among school age children age to injuries lead to million emergency department ED visits and hospital admissions annually resulting in $ billion in medical costs and $ billion more in work loss costs Approxima ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Urocortin Gene Transfer for CHF a Paracrine Approach Using Intravenous AAV

    SBC: Renova Therapeutics, Inc.            Topic: NHLBI

    DESCRIPTION provided by applicant Gene transfer for the treatment of cardiovascular diseases is bedeviled by inability to obtain safely and easily sufficient cardiac transgene expression Current methods of gene transfer for heart disease include intramuscular injection into heart muscle or intracoronary delivery approaches that are cumbersome to apply Consequently we have considered the u ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Bone targeted antimicrobials for biofilm-mediated osteolytic infection treatment

    SBC: BIOVINC, LLC            Topic: NIDCR

    DESCRIPTION provided by applicant Infectious bone disease is a major cause of morbidity and mortality worldwide Successful treatment often requires surgical intervention with longer term antibiotic therapy Bacterial biofilm pathogens are associated with most osseous infections and represent a major target of therapy The biofilm pathogens associated with chronic bone infections bind to and co ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. An epitope focused nanoparticle vaccine for MRSA and biodefense

    SBC: VLP BIOTECH, INC.            Topic: NIAID

    DESCRIPTION provided by applicant Overall Staphylococcus aureus is a gram positive bacteria which possesses a multitude of virulence factors It is a frequent and severe pathogen in hospitals and of increasing concern in the community where it results in severe skin infections pneumonia bacterial endocarditis and sepsis A significant proportion of these infections are the result of methici ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. improving Cas9 mediated homologous recombination in pluripotent stem cells

    SBC: APPLIED STEMCELL, INC.            Topic: 200

    DESCRIPTION provided by applicant Gene correction therapy is one of the most important application directions in regenerative medicine Scientists are exploring various approaches to introduce targeted mutations corrections to pluripotent stem cells PSCs to establish disease models and or to develop therapeutic agents Emerging technologies such as Zinc Finger Nucleases ZFNs Transcription ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Preclinical Testing of a Novel Flow Diverting Stent for Treating Intracranial Aneurysms

    SBC: NeuroSigma, Inc.            Topic: 101

    DESCRIPTIONprovided by applicantThe purpose of this project is to develop an improvedminimally invasive treatment for intracranial aneurysmsIntracranial aneurysms are spherical outpouchings of blood vessels in the head that result from weakness in the vessel wallUnruptured aneurysms are present in approximatelyof the general populationand rupture can be devastating with a high morbidity and mortal ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Optimization of the Production and Isolation of the Novel Antifungal Occidiofungin

    SBC: Sano Chemicals, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant Occidiofungin is a cyclic nonribosomally synthesized antifungal peptide with submicromolar fungicidal activity against a broad spectrum of fungi Occidiofungin is produced by the Gram negative bacterium Burkholderia contaminans From our structural characterization studies occidiofungin was determined to have a unique chemical composition Our studies have als ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. A method for accurate and sensitive detection of HIV drug-resistant minority variants

    SBC: Medosome Biotec, LLC            Topic: NIAID

    DESCRIPTION provided by applicant Drug resistance to HIV is a major threat to achieving long term viral suppression in HIV individuals Up to of newly infected individuals acquire HIV with resistance to at least one of the major antiretroviral classes and incomplete viral suppression and virologic failure are often associated with drug resistance Therefore current DHHS guideline recomme ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Modulation of the Innate Immune Response by Fisetin Derivatives for the Treatment of AD

    SBC: VIROGENICS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant There are currently no drugs or other therapeutic interventions that can reverse or halt the progression of Alzheimerandapos s disease AD Age is by far the greatest risk factor for AD and it is known from studies in both mice and humans that neuroinflammation is increased with old age and to an even greater extent in AD Therefore a drug that could reduce ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government